{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T03:33:27Z","timestamp":1789356807192,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,4,2]],"date-time":"2011-04-02T00:00:00Z","timestamp":1301702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s11940-011-0121-1","type":"journal-article","created":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T11:47:40Z","timestamp":1301658460000},"page":"242-254","source":"Crossref","is-referenced-by-count":23,"title":["Dementia in Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"13","author":[{"given":"Avrom L.","family":"Kurtz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel I.","family":"Kaufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,2]]},"reference":[{"key":"121_CR1","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1212\/01.wnl.0000256715.13907.d3","volume":"68","author":"CF Lippa","year":"2007","unstructured":"Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68:812\u20139.","journal-title":"Neurology"},{"key":"121_CR2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archneur.60.3.387","volume":"60","author":"D Aarsland","year":"2003","unstructured":"Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60:387\u201392.","journal-title":"Arch Neurol"},{"key":"121_CR3","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord. 2007;22:1689\u2013707.","journal-title":"Mov Disord"},{"key":"121_CR4","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","volume":"47","author":"IG McKeith","year":"1996","unstructured":"McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology. 1996;47:1113\u201324.","journal-title":"Neurology"},{"key":"121_CR5","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","volume":"65","author":"IG McKeith","year":"2005","unstructured":"McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863\u201372.","journal-title":"Neurology"},{"key":"121_CR6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000072807","volume":"16","author":"D Collerton","year":"2003","unstructured":"Collerton D, Burn D, McKeith I, O\u2019Brien J. Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cog Disord. 2003;16:229\u201337.","journal-title":"Dement Geriatr Cog Disord"},{"key":"121_CR7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/mds.20726","volume":"21","author":"CC Janvin","year":"2006","unstructured":"Janvin CC, Larsen JP, Salmon DP, et al. Cognitive profiles of individual patients with Parkinson\u2019s disease and dementia: comparison with dementia with Lewy bodies and Alzheimer\u2019s disease. Mov Disord. 2006;21:337\u201342.","journal-title":"Mov Disord"},{"key":"121_CR8","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/jnnp.2006.108076","volume":"78","author":"K Bronnick","year":"2007","unstructured":"Bronnick K, Emre M, Lane R. Profile of cognitive impairment in dementia associated with Parkinson\u2019s disease compared with Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2007;78:1064\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"121_CR9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"3","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;3:189\u201398.","journal-title":"J Psychiatr Res"},{"key":"121_CR10","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jamda.2008.05.006","volume":"9","author":"DI Kaufer","year":"2008","unstructured":"Kaufer DI, Williams SC, Braaten AJ, Gill K, Zimmerman S, Sloane PD. Cognitive screening for dementia and mild cognitive impairment in assisted living: comparison of three tests. J Am Med Dir Assoc. 2008;9:586\u201393.","journal-title":"J Am Med Dir Assoc"},{"key":"121_CR11","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment (MoCA): a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"121_CR12","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1532-5415.2008.02096.x","volume":"57","author":"S Nazem","year":"2009","unstructured":"Nazem S, Siderowf AD, Duda JE, et al. Montreal Cognitive Assessment performance in patients with Parkinson\u2019s disease with \"normal\" global cognition according to Mini-Mental State Examination score. J Am Geriatr Soc 2009;57:304\u20138.","journal-title":"J Am Geriatr Soc"},{"key":"121_CR13","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/mds.21844","volume":"16","author":"B Dubois","year":"2007","unstructured":"Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson\u2019s disease dementia: recommendations from the Movement Disorder Society task force. Mov Disord. 2007;16:2314\u201324.","journal-title":"Mov Disord"},{"key":"121_CR14","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","volume":"356","author":"IG McKeith","year":"2000","unstructured":"McKeith IG, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356:2031\u20136.","journal-title":"Lancet"},{"key":"121_CR15","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","volume":"351","author":"M Emre","year":"2004","unstructured":"Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson\u2019s disease. N Engl J Med. 2004;351:2509\u201318.","journal-title":"N Engl J Med"},{"key":"121_CR16","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/jnnp.72.6.708","volume":"72","author":"D Aarsland","year":"2002","unstructured":"Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson\u2019s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002;72:708\u201312.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"121_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/gps.993","volume":"19","author":"I Leroi","year":"2004","unstructured":"Leroi I, Brandt J, Reich SG, et al. Randomized trial of donepezil in cognitive impairment in Parkinson\u2019s disease. Int J Geriatr Psychiatry. 2004;19:1\u20138.","journal-title":"Int J Geriatr Psychiatry"},{"key":"121_CR18","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/jnnp.2004.050682","volume":"76","author":"B Ravina","year":"2005","unstructured":"Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson\u2019s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76:934\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"121_CR19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1159\/000101512","volume":"23","author":"K Edwards","year":"2007","unstructured":"Edwards K, Royall D, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dem Geriatr Cog Disord. 2007;23:401\u20135.","journal-title":"Dem Geriatr Cog Disord"},{"key":"121_CR20","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","volume":"8","author":"D Aarsland","year":"2009","unstructured":"Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8:613\u20138.","journal-title":"Lancet Neurol"},{"key":"121_CR21","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","volume":"10","author":"M Emre","year":"2010","unstructured":"Emre M, Tsolaki M, Bonuccelli U, et al. on behalf of the 11018 Study Investigators. Memantine for patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;10:969\u201377.","journal-title":"Lancet Neurol"},{"key":"121_CR22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2869.2005.00445.x","volume":"14","author":"RE Tractenberg","year":"2005","unstructured":"Tractenberg RE, Singer CM, Kaye JA. Symptoms of sleep disturbance in persons with Alzheimer\u2019s disease and the normal elderly. J Sleep Res. 2005;14:177\u201385.","journal-title":"J Sleep Res"},{"key":"121_CR23","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1212\/01.wnl.0000209264.61035.bb","volume":"66","author":"BF Boeve","year":"2006","unstructured":"Boeve BF, Saper CB. REM sleep behavior disorder; a possible early marker for synucleinopathies. Neurology. 2006;66:796\u20137.","journal-title":"Neurology"},{"key":"121_CR24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/sleep\/25.2.120","volume":"25","author":"CH Schenck","year":"2002","unstructured":"Schenck CH, Mahowald MW. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16\u00a0years after its formal identification in Sleep. Sleep. 2002;25:120\u201338.","journal-title":"Sleep"},{"key":"121_CR25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/sleep\/9.2.293","volume":"9","author":"CH Schenck","year":"1986","unstructured":"Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep. 1986;9:293\u2013308.","journal-title":"Sleep"},{"key":"121_CR26","first-page":"85","volume":"61","author":"RN Aurora","year":"2010","unstructured":"Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). American Academy of Sleep Medicine. J Clin Sleep Med. 2010;61:85\u201395.","journal-title":"J Clin Sleep Med"},{"key":"121_CR27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1389-9457(03)00072-8","volume":"4","author":"B Boeve","year":"2003","unstructured":"Boeve B, Silber M, Ferman T. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: Results in 14 patients. Sleep Med. 2003;4:281\u20134.","journal-title":"Sleep Med"},{"key":"121_CR28","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/gps.2506","volume":"25","author":"V Larsson","year":"2010","unstructured":"Larsson V, Aarsland D, et al. The effect of memantine on sleep behavior in dementia with Lewy bodies and Parkinson\u2019s disease dementia. Int J Geriatr Psychiatry. 2010;25:1030\u20138.","journal-title":"Int J Geriatr Psychiatry"},{"key":"121_CR29","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/sleep\/25.8.62","volume":"25","author":"B Hogl","year":"2002","unstructured":"Hogl B, Saletu B, et al. Modafinil for the treatment of daytime sleepiness in Parkinson\u2019s disease: A double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002;25:905\u20139.","journal-title":"Sleep"},{"key":"121_CR30","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/mds.10390","volume":"18","author":"CH Adler","year":"2003","unstructured":"Adler CH, Caviness JN, Hentz JG, et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson\u2019s disease. Mov Disord. 2003;18:287\u201393.","journal-title":"Mov Disord"},{"key":"121_CR31","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/jnnp.2005.065870","volume":"76","author":"WG Ondo","year":"2005","unstructured":"Ondo WG, Fayle R, Atassi F, et al. Modafinil for daytime somnolence in Parkinson\u2019s disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005;76:1636\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"121_CR32","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/archneur.65.10.1337","volume":"65","author":"WG Ondo","year":"2008","unstructured":"Ondo WG, Perkins T, Swick T, et al. Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study. Arch Neurol. 2008;65:1337\u201340.","journal-title":"Arch Neurol"},{"key":"121_CR33","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1212\/01.WNL.0000125192.69777.6D","volume":"62","author":"P Thaisetthawatkul","year":"2004","unstructured":"Thaisetthawatkul P, Boeve B, Ferman T, et al. Autonomic dysfunction in Lewy body dementia. Neurology. 2004;62:1804\u20139.","journal-title":"Neurology"},{"key":"121_CR34","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/mds.21428","volume":"22","author":"KL Schoffer","year":"2007","unstructured":"Schoffer KL, Henderson RD, O\u2019Maley K, O\u2019Sullivan JD. Nonpharmacological treatment, fludrocortisone and domperidone for orthostatic hypotension in Parkinson\u2019s disease. Mov Disord. 2007;22:1543\u20139.","journal-title":"Mov Disord"},{"key":"121_CR35","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1001\/jama.2010.1695","volume":"304","author":"SS Dhruva","year":"2010","unstructured":"Dhruva SS, Redberg RF. Accelerated approval and possible withdrawal of midodrine. JAMA 2010;304:2172\u20133.","journal-title":"JAMA"},{"key":"121_CR36","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/archneur.63.4.noc50340","volume":"63","author":"W Singer","year":"2006","unstructured":"Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006;63:513\u20138.","journal-title":"Arch Neurol"},{"key":"121_CR37","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1136\/jnnp.74.9.1294","volume":"74","author":"W Singer","year":"2003","unstructured":"Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2003;74:1294\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"121_CR38","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/HYPERTENSIONAHA.110.154898","volume":"56","author":"C Shibao","year":"2010","unstructured":"Shibao C, Okamoto LE, Gamboa A, et al. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2010;56:847\u201351.","journal-title":"Hypertension"},{"key":"121_CR39","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/mds.20867","volume":"21","author":"K Winge","year":"2006","unstructured":"Winge K, Fowler CJ. Bladder dysfunction in parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord. 2006;21:737\u201345.","journal-title":"Mov Disord"},{"key":"121_CR40","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jns.2009.08.020","volume":"289","author":"JH Wolfgang","year":"2010","unstructured":"Wolfgang JH. Gastrointestinal dysfunction in Parkinson\u2019s disease. J Neurol Sci. 2010;289:69\u201373.","journal-title":"J Neurol Sci"},{"key":"121_CR41","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ijir.2010.23","volume":"22","author":"MR Safarinejad","year":"2010","unstructured":"Safarinejad MR, Taghva A, Shekarchi B, et al. Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, placebo-controlled, randomized study. Int J Impot Res. 2010; 22:325\u201335.","journal-title":"Int J Impot Res."},{"key":"121_CR42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1212\/01.WNL.0000101713.81253.4C","volume":"62","author":"WG Ondo","year":"2004","unstructured":"Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson\u2019s disease. Neurology. 2004;62:37\u201340.","journal-title":"Neurology"},{"key":"121_CR43","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/mds.21803","volume":"23","author":"JS Reijnders","year":"2008","unstructured":"Reijnders JS, Ehrt U, Weber WE, et al. A systemic review of prevalence studies of depression in Parkinson\u2019s disease. Mov Disord. 2008;23:183\u20139.","journal-title":"Mov Disord"},{"key":"121_CR44","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","volume":"72","author":"A Menza","year":"2009","unstructured":"Menza A, Dobkin R D, et al. Controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72:886\u201392.","journal-title":"Neurology"},{"key":"121_CR45","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1479-8301.2009.00292.x","volume":"9","author":"S Takahashi","year":"2009","unstructured":"Takahashi S, Mizukami K, et al. Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy. Psychogeriatrics. 2009;9:56\u201361.","journal-title":"Psychogeriatrics"},{"key":"121_CR46","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.parkreldis.2010.05.004","volume":"16","author":"JH Friedman","year":"2010","unstructured":"Friedman JH. Parkinson\u2019s disease psychosis 2010: a review article. Parkinsonism Relat Disord. 2010;16:553\u201360.","journal-title":"Parkinsonism Relat Disord."},{"key":"121_CR47","doi-asserted-by":"crossref","first-page":"775","DOI":"10.7326\/0003-4819-146-11-200706050-00006","volume":"146","author":"SS Gill","year":"2007","unstructured":"Gill SS, Bronskill SE, Normand SL. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146:775\u201386.","journal-title":"Ann Intern Med"},{"issue":"Suppl 11","key":"121_CR48","first-page":"16","volume":"65","author":"A Baskys","year":"2004","unstructured":"Baskys A. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry. 2004;65 Suppl 11:16\u201322.","journal-title":"J Clin Psychiatry"},{"key":"121_CR49","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20474","volume":"20","author":"WG Ondo","year":"2005","unstructured":"Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson\u2019s disease. Mov Disord. 2005;20:958\u201363.","journal-title":"Mov Disord"},{"key":"121_CR50","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.21116","volume":"22","author":"JM Rabey","year":"2007","unstructured":"Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson\u2019s disease patients: a double-blind labeled study of 3\u00a0months duration. Mov Disord. 2007;22:313\u20138.","journal-title":"Mov Disord"},{"key":"121_CR51","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1007\/s100720200084","volume":"23","author":"L Morgante","year":"2002","unstructured":"Morgante L, Epifanio A, Spina E, et al. Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson\u2019s disease. Neurol Sci. 2002;23:S89\u201390.","journal-title":"Neurol Sci"},{"key":"121_CR52","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","volume":"340","author":"The Parkinson Study Group","year":"1999","unstructured":"The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. N Engl J Med. 1999;340:757\u201363.","journal-title":"N Engl J Med"},{"key":"121_CR53","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","volume":"353","author":"The French Clozapine Parkinson Study Group","year":"1999","unstructured":"The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson\u2019s disease. Lancet. 1999;353:2041\u20132.","journal-title":"Lancet"},{"key":"121_CR54","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/mds.21091","volume":"21","author":"JH Friedman","year":"2006","unstructured":"Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson\u2019s disease. Mov Disord. 2006;21:2078\u201381.","journal-title":"Mov Disord"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-011-0121-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-011-0121-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-011-0121-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T16:02:31Z","timestamp":1560096151000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-011-0121-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,2]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["121"],"URL":"https:\/\/doi.org\/10.1007\/s11940-011-0121-1","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,2]]}}}